Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Verastem Oncology revenue increased from $17.5 million in 2019 to $88.5 million in 2020, a (407.1%) increase.

Annual Revenue ($)

Verastem Oncology revenue was $88.52 m in FY, 2020 which is a (407.1%) year over year increase from the previous period.

Quarterly Revenue ($)

FY, 2018FY, 2019FY, 2020
Revenue$26.72 m$17.46 m$88.52 m
Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021
Revenue$1.67 m$3.14 m$9.03 m$5.06 m$4.31 m$78.65 m$1.01 m$500 k

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

Verastem Oncology revenue breakdown by business segment: 17.2% from Product Revenue, 79.1% from Sale of COPIKTRA License and 3.7% from Other

FY, 2020FY, 2019FY, 2018
Product Revenue$15.23 m$12.34 m$1.72 m
License and Collaboration Revenue$2.91 m$5.12 m$25 m
Sale of COPIKTRA License$70 m
Transition Services Revenue$372 k

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu